$ALMR News

Alamar Biosciences: Promising But Expensive Proteomics Growth

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32

Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum

JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

Alamar Biosciences Sees FY2026 Sales $116.000M-$120.000M vs $113.259M Est

Alamar Biosciences Launches NULISAseq Immune 340 Panel, Broadest Multiplexed Immune Profiling Solution Available For Translational Research And Drug Development

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Evaluating Alamar Biosciences (ALMR) Valuation As Shares Show Modest Year To Date Gains

TD Cowen Initiates Coverage On Alamar Biosciences with Buy Rating, Announces Price Target of $30

JP Morgan Initiates Coverage On Alamar Biosciences with Overweight Rating, Announces Price Target of $30

Stifel Initiates Coverage On Alamar Biosciences with Buy Rating, Announces Price Target of $28

Alamar Biosciences Reports First Quarter 2026 Financial Results

Alamar Biosciences Q1 EPS $(1.74), Sales $26.035M

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference

Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

Qiming Venture Partners-Backed Alamar Biosciences Lists On NASDAQ, Issues Shares At $17, Opens At $22.6 With $1.5B Valuation

Qiming Venture Partners-Backed Alamar Biosciences Lists On NASDAQ, Issues Shares At $17, Opens At $22.6 With $1.5B Valuation